Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01CX001864-01A1 |
| Title: | Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia. |
| Principal Investigator: | Elizabeth A. Eklund |
| Location: | Chicago, IL |
| Congressional District Code: | 7 |
| Research Service: | Clinical Science R&D |
| Project Period: | April 2019 - March 2023 |
| FY 2021 Funding Amount: | $165,000 |
| Total Award Amount (all years): |
$710,000 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Clinical outcomes in chronic myeloid leukemia (CML) were revolutionized by development of imatinib (IM) and later generation tyrosine kinase inhibitors (TKIs) that target the Bcr-abl oncogene. Currently, ~55% patients with newly diagnosed CML achieve a major molecular response to TKI treatment (MMR) and 17% a complete molecular response (CMR). Because CML patients survive many years, there is interest in identifying those who can discontinue treatment. This interest is encouraged by the 30% inci... |